FDA Class II Recall: Golden State Medical Supply's Fluticasone Propionate Nasal Spray Pulled Over Burkholderia cepacia Complex Contamination
Golden State Medical Supply initiated a nationwide Class II recall of 59,712 bottles of Fluticasone Propionate Nasal Spray due to suspected *Burkholderia cepacia complex* contamination, stemming from significant CGMP deviations at manufacturer Apotek Inc. This event signals critical regulatory non-compliance, necessitating immediate supply chain review for procurement directors and heightened quality assurance for all stakeholders.
FDA Class II Recall: CGMP Deviations Lead to Fluticasone Propionate Contamination
Golden State Medical Supply, Inc., based in Camarillo, CA, has initiated a voluntary, firm-initiated Class II recall of 59,712 bottles of its Fluticasone Propionate Nasal Spray USP, 50 mcg per spray. This significant regulatory action stems from suspected potential presence of *Burkholderia cepacia complex*, a critical microbial contaminant, indicating severe Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility, Apotek Inc. in Toronto, Ontario, Canada. For procurement directors, this recall mandates an immediate review of all existing inventory and supply contracts related to Fluticasone Propionate, specifically Lot #: TX5275 with an expiration date of October 31, 2026. The presence of *Burkholderia cepacia complex* in a nasal spray is particularly concerning, as it is an opportunistic pathogen that poses a heightened risk to immunocompromised individuals or those with cystic fibrosis, potentially leading to serious respiratory infections. Regulatory affairs heads must recognize that such CGMP deviations, particularly those involving microbial contamination, are often precursors to more stringent FDA enforcement actions, including 483 observations, Warning Letters, or even Import Alerts for foreign manufacturers. The Class II classification signifies that exposure to the violative product may cause temporary or medically reversible adverse health consequences, underscoring the urgency for businesses to address this supply chain disruption and potential patient safety risk.
Product and Supply Chain Profile: Fluticasone Propionate Nasal Spray Distribution
The recalled product, Fluticasone Propionate Nasal Spray USP, 50 mcg per spray, is a human prescription drug packaged as 120 metered sprays in a 16 g net fill bottle. Marketed by Golden State Medical Supply, Inc. (NDC 60429-195-15) and manufactured by Apotek Inc., this generic corticosteroid nasal spray is widely used for the treatment of seasonal and perennial allergic rhinitis. The specific product involved in this recall holds FDA Application Number ANDA077538, indicating its approval as a generic drug. The distribution pattern for the affected Lot #: TX5275 was nationwide across the USA, meaning the contaminated product could be present in pharmacies, hospitals, and other healthcare facilities throughout the country. For supply chain VPs, this nationwide distribution highlights the extensive reach of the contamination risk and the complexity of managing product retrieval. It underscores the critical need for robust traceability systems to quickly identify and isolate affected batches. Business development executives should note the dual entity involvement—Golden State Medical Supply as the marketer and Apotek Inc. as the manufacturer—which emphasizes the importance of stringent quality agreements and shared responsibility in the pharmaceutical supply chain. Any disruption to the supply of a commonly prescribed generic like Fluticasone Propionate can lead to market shortages and impact patient access, requiring proactive mitigation strategies from all stakeholders.
Regulatory Implications: Heightened Scrutiny on Sterility Assurance and CGMP Compliance
The identification of *Burkholderia cepacia complex* and the underlying CGMP Deviations represent a severe breach of regulatory standards, placing both Golden State Medical Supply and its manufacturer, Apotek Inc., under intense FDA scrutiny. Regulatory affairs heads should prepare for potential FDA inspections at Apotek Inc.'s Toronto facility, focusing on their sterile manufacturing processes, environmental monitoring programs, water systems, and overall quality management systems. The FDA's classification of this as a Class II recall, while not the most severe, still indicates a significant health risk, particularly given the product's nasal route of administration and the opportunistic nature of the pathogen. This event serves as a stark reminder that even generic drug products are subject to the highest standards of quality and sterility. For business development executives, this incident signals a need to re-evaluate partnerships with manufacturers and marketers who demonstrate lapses in CGMP compliance, as such issues can severely impact market access, product reputation, and long-term commercial viability. The ongoing status of the recall indicates that the FDA is actively monitoring the firm's corrective actions, and failure to adequately address the root causes of these deviations could lead to escalated enforcement, including potential import alerts for Apotek Inc.'s Canadian facility, effectively barring their products from the U.S. market.
Procurement and Business Continuity: Sourcing Alternatives for Fluticasone Propionate
Procurement directors must immediately assess their current sourcing strategies for Fluticasone Propionate and activate contingency plans. Given the nationwide distribution of the recalled product and the severity of the CGMP deviations, reliance on Golden State Medical Supply and its manufacturing partner, Apotek Inc., for this specific product is now subject to significant risk. While the ChemLifeIntel Knowledge Graph does not identify specific alternative suppliers for Fluticasone Propionate in this context, procurement teams should proactively identify and begin the qualification process for new, FDA-compliant manufacturers. This process typically involves rigorous audits, analytical testing, and regulatory documentation review, which can take several months to over a year to complete. The commercial impact of a supply disruption for a widely used generic like Fluticasone Propionate can be substantial, affecting patient access and potentially leading to market share shifts. Business development executives should prioritize engaging with partners who demonstrate a robust track record of regulatory compliance and proactive quality management. This incident underscores the strategic imperative for diversified sourcing, geographic redundancy, and comprehensive supplier qualification programs to build resilience against unforeseen quality and regulatory challenges in the pharmaceutical supply chain.
Remediation Timeline and Future Regulatory Oversight for Golden State Medical Supply
The recall of Fluticasone Propionate Nasal Spray was initiated by Golden State Medical Supply on February 14, 2024, with the FDA classifying it on February 23, 2024, and the event being reported on March 6, 2024. As a firm-initiated voluntary recall, this indicates Golden State Medical Supply's proactive response to the identified quality issue. However, the 'Ongoing' status of the recall means that both Golden State Medical Supply and Apotek Inc. are expected to undertake comprehensive remediation efforts. Regulatory affairs and quality assurance teams must ensure a thorough root cause investigation into the *Burkholderia cepacia complex* contamination and the underlying CGMP deviations. This includes implementing robust Corrective and Preventive Actions (CAPA) that address environmental controls, aseptic processing, personnel training, and quality oversight at Apotek Inc.'s manufacturing site. The FDA will closely monitor the effectiveness of these CAPAs through follow-up inspections and reviews of submitted documentation. For supply chain VPs, the long-term viability of Apotek Inc. as a manufacturer for the U.S. market, and Golden State Medical Supply as a marketer, will depend heavily on their ability to demonstrate sustainable compliance. Failure to effectively remediate these issues could lead to further FDA enforcement actions, impacting their ability to supply other products to the U.S. market and potentially resulting in significant commercial penalties and reputational damage.